ArticleClinical rheumatology2026
Metformin use and risk of all-cause mortality in US adults with arthritis: a cohort study from NHANES 1999-2018.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAdults with arthritis face an elevated risk of all-cause mortality. While baseline-reported metformin use is associated with lower mortality in other chronic conditions, whether a similar association exists in this high-risk population remains unknown. We therefore aimed to evaluate the association between baseline-reported metformin use and all-cause mortality in a large, population-based cohort of US adults with arthritis.
methodsThis cohort study analyzed data from 14,633 participants with self-reported arthritis in the National Health and Nutrition Examination Survey, 1999-2018. Participants were categorized as baseline-reported metformin users or non-users based on the 30-day prescription medication inventory collected during the baseline in-home interview. The study outcome was all-cause mortality, ascertained via linkage to the National Death Index. We used multivariable Cox proportional hazards models to estimate hazard ratios (HRs), complemented by propensity score-based analyses, including inverse probability of treatment weighting.
resultsThe cohort, with a mean age of 62.87 years and 59.61% female, was followed for a median of 95 months, during which 4412 deaths occurred. After multivariable adjustment, baseline-reported metformin use was associated with a significantly lower risk of all-cause mortality (HR, 0.77; 95% confidence interval [CI] 0.68-0.86; P < 0.001). Propensity score analyses substantiated these findings, yielding an HR of 0.76 (95% CI 0.67-0.86, P < 0.001). The association was consistent across different arthritis subtypes and in various sensitivity analyses.
conclusionOur study found that baseline-reported metformin use was associated with a significantly lower risk of all-cause mortality among US adults with arthritis. Given the observational nature of this study and potential confounding by indication, these findings should be interpreted as associative rather than causal. Additional research is required to substantiate these findings. Key Points • Baseline-reported metformin use was associated with a significantly lower risk of all-cause mortality in adults with arthritis. • The association between baseline-reported metformin use and lower all-cause mortality was consistent across different arthritis subtypes.
Indexed as
Identifiers
41917541What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.